Funding to Advance “Next Generation” Vaccine
Proceeds from the Series B round will support further development of ILiAD’s lead vaccine candidate, BPZE1. The company describes BPZE1 as a “next generation” approach designed to deliver broad and durable immunity, aiming to prevent infection, disease and transmission of Bordetella pertussis.
Unlike traditional shots, BPZE1 is administered without a needle, a feature the company says could widen access and acceptance. By stimulating mucosal immunity — the body’s frontline defense in the respiratory tract — the vaccine is intended to mirror a more natural immune response.
ILiAD said it plans to begin a human challenge trial of BPZE1 later this year, with data anticipated in 2027. The upcoming trial will test whether the candidate can withstand direct exposure to the pathogen — a high-stakes proving ground in vaccine development.
Investors Rally Behind the Science
The ILiAD $115M Fundraise was led by RA Capital Management, with participation from new investors Janus Henderson Investors and BNP Paribas Asset Management Alts. Existing backers, including AI Life Sciences, also joined the round.
ILiAD founder and CEO Keith Rubin said the financing underscores both the urgency of the public health need and confidence in the company’s approach.
“Today’s financing reflects the urgent need for better pertussis vaccines, the scientific rigor and operational discipline of our team, and the extraordinary potential BPZE1 holds to improve global public health,” Rubin said. He thanked RA Capital for leading the round and acknowledged Janus, BNPP AM Alts and earlier investors for their support in advancing the company’s mission to eradicate pertussis.
